Paroxetine: A review of clinical experience

Pharmacopsychiatry

Volumn 31, Issue 3, 1998, Pages 89-101

  Dunner, D ^a   Kumar, R ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; PAROXETINE; PINDOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG RESISTANCE; HUMAN; META ANALYSIS; OBSESSION; PANIC; PRIORITY JOURNAL; SIDE EFFECT; SUICIDAL BEHAVIOR; TRANQUILIZING ACTIVITY;

EID: 0031832993     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979307     Document Type: Article

References (136)

1. AHCPR Clinical Guideline Number 5. Depression in Primary Care, Volume 2: Treatment of major depression. AHCPR Publication no. 93-0551, 1993
2. Aguglia, E., M. Casacchia, C. B. Cassano, C. Faravelli, G. Ferrari, P. Giordiano, P. Pancheri, L. Ravizza, M. Trabucchi, F. Bolino: Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int. Clin. Psychopharmacol, 8 (1993) 197-202
3. Angst, J.: Comorbidity of anxiety, phobia, compulsion and depression. Int. Clin. Psychopharmacol. 8 (1993, Suppl. 1) 21-25
4. Angst, J: How recurrent and predictable is depressive illness? In: Montgomery, S., F. Rouillon (eds.): Perspectives in Psychiatry Vol. 3. Wiley, Chichester (1992) pp. 1-13
5. Ansseau, M., A. Gabriels, J. Loyens, F. Bartholome, J. L. Evrard, A. de Noyer, R. Linhart, J. Wirtz, F. Bruynooghe, K. Surinx, H. Clarysse, R. Marganne, P. Papart: Controlled comparison of paroxetine and fluvoxamine in major depression. Human Psychopharmacol. 9 (1994) 329-336
6. Arminen, S. -L., U. Ikonen, P. Pulkkinen, E. Leinonen, A. Mahlanen, H. Koponen, K. Kourula, J. Ryyppo, V. Korpela, M. L. Lehtonen, H. Vartiainen, V. Lehtinen, T. Tarnminen, P. M. Manniche: A 12-week, double-blind multi-centre study of paroxetine and imipramine in hospitalized patients. Acta Psychiatr. Scand. 89 (1994) 382-389
7. Baldwin, J. A., E. J. Davidson, A. L. Pritchard, J. E. Ridings: The reproductive toxicology of paroxetine. Acta Psychiatr. Scand. 350 (1989) 37-39
8. Bannister, S. J., V. P. Houser, J. D. Hulse, J. C. Kisicki, J. G. C. Rasmussen: Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin and digoxin. Acta Psychiatr. Scand. 80 (1989, Suppl. 350) 102-106
9. Bascara, L.: A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta Psychiatr. Scand 80 (1989, Suppl. 350) 141-142
10. Bergstrom, R. E., A. L Peyton, L. Lemberger: Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin. Pharmacol. Ther. 51 (1992) 239-248
11. Bignamini, A., V. Rapisarda: A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients. Int. Clin. Psychopharmacol. 6 (1992, Suppl. 4) 37-41
12. Blier, P., R. Bergeron: Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15 (1995) 217-222
13. Boyer, W. F., J. P. Feighner: Other potential indications for selective serotonin re-uptake inhibitors. In: Boyer, W. F., J. P. Feighner (eds.): Selective serotonin reuptake inhibitors. John Wiley, Chichester (1991a) pp. 119-132
14. Boyer, W. F., J. P. Feighner: Pharmacokinetics and drug interactions. In: Boyer, W. F., J. P. Feighner (eds.): Selective serotonin reuptake inhibitors. John Wiley, Chichester (1991b) pp. 81-88
15. Brosen, K., J. C. Hansen, K. K. Nielsen, S. H. Sindrup, L. F. Gram: Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur. J. Pharmacol. 44 (1993) 349-355
16. Cain, C. R., T. C. Hamilton, J. Norton, E. N. Petersen, R. H. Poyser, D. Thormählen: Relative lack of cardiotoxicity of paroxetine in animal models. Acta Psychiatr. Scand. 80 (1989, suppl. 350) 27-30
17. Calabrese, D. C., D. I. Brixner, M. S. Hildebrand: Analysis of selective serotonin reuptake inhibitor utilization in a group model managed care setting. Presented at the Academy for Managed Care Pharmacy, Anaheim, 1994
18. Christiansen, P. E.: Paroxetine and imipramine in the treatment of depressed patients in psychiatric specialist practice. Nord. J. Psychiat. 46 (1992, Suppl. 27) 33-39
19. Claghorn, J.: A double-blind comparison of paroxetine and placebo in the treatment of depressed outpatients. Int. Clin. Psychopharmacol. 6 (1992, Suppl. 4) 25-30
20. Claghorn, J.: Paroxetine: Long-term efficacy and tolerability. Presented at the 5th World Congress of Biological Psychiatry, Florence, 1991
21. Claghorn, J. L., J. P. Feighner: A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. J. Clin. Psychopharmacol. 13 (1993, Suppl. 2) 23-27
22. Claghorn, J. L., A. Kiev, K. Rickels, W. T. Smith, G. C. Dunbar: Paroxetine versus placebo: a double-blind comparison in depressed patients. J. Clin. Psychiatry 53 (1992) 434-438
23. Cohen, G. D.: Prevalence of psychiatric problems in older adults. Psychiatric Ann. 20 (1990) 433-438
24. Cohn, C. K., R. Shrivastava, J. Mendels, J. B. Conn, L. E. Fabre, J. L. Claghorn, E. C. Dessain, T. M. Itil, A. Lautin: Double-blind, multicenter comparison of sertraline and amytriptyline in elderly depressed patients. J. Clin. Psychiatry 5 (1990, Suppl. B) 28-33
25. Cooper, S. M., D. Jackson, J. M. Louden, G. R. McClelland, P. Raptopoulos: The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam or alcohol. Acta Psychiatr. Scand. 80 (1989, Suppl. 350) 53-55
26. Coplan, J. D., J. M. Gorman, D. F. Klein: Serotonin related functions in panic-anxiety: a critical overview. Neuropsychopharmacology 6 (1992) 189-200
27. Coulehan, J. L., H. C. Schulberg, M. R. Block, J. E. Janosky, V. C. Arena: Medical co-morbidity of major depressive disorder in a primary medical practice. Arch. Int. Med. 150 (1990) 2363-2367
28. Crewe, H. K., M. S. Lennard, C. T. Tucker, F. R. Woods, R. E. Haddock: The effect of selective serotonin reuptake inhibitors on cytochrome P450 2D6 (CYP 2D6) activity in human liver microsomes. Br. J. Pharmacol. 34 (1992) 262-265
29. Donish University Antidepressant Group: Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 18 (1990) 289-299
30. De Wilde, J., S. M. Loriaux, J. F. Orlebeke, J. de Vries: A double-blind, comparative, multicentre study comparing paroxetine and fluoxetine in depressed patients. Acta Psychiatr. Scand. 87 (1993) 141-145
31. Dorman, T.: Sleep and paroxetine: a comparison with mianserin in elderly depressed patients. Int. Clin. Psychopharmacol. 6 (1992, Suppl.) 53-58
32. Duboff, E. A.: Long-term treatment of major depressive disorder with paroxetine. J. Clin. Psychopharmacol. 13 (1993, Suppl. 2) 28-33
33. Dunbar, G. C., J. L. Claghorn, A. Kiev, K. Rickels, W. T. Smith: A comparison of paroxetine and placebo in depressed outpatients. Acta Psychiatr. Scand. 87 (1993) 303-305
34. Dunbar, G. C., J. B. Cohn, L. F. Fabre, J. P. Feighner, R. R. Fieve, J. Mendels, R. K. Shrivastava: A comparison of paroxetine, imipramine, and placebo in depressed out-patients. Br. J. Psychiatry 159 (1991) 394-398
35. Dunbar, G. C., D. L. Fuell: The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int. Clin. Psychopharmacol. 6 (1992) 81-90
36. Dunbar, G. C., R. Judge: Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Eur. Neuropsychopharmacol. 5 (1995) 361, Abstract P5-27
37. Dunbar, G. C., M. Steiner, R. Oakes, I. Gergel, D. Burnham, D. E. Wheadon: A fixed dose study of paroxetine (10mg, 20 mg, 40 mg) and placebo in the treatment of panic disorder. Eur. Neuropsychopharmacol. 5 (1995) 361, Abstract P5-26
38. Dunbar, G. C.: Paroxetine in the elderly: a comparative metaanalysis against standard antidepressant pharmacotherapy. Pharmacology 51 (1995) 137-144
39. Dunner, D. L., J. B. Cohn, T. Walsche, C. K. Cohn, J. P. Feighner, R. R. Fieve, J. P. Halikas, J. T. Hartford, E. D. Hearst, E. C. Settle, F. J. Menolascino, D. J. Muller: Two combined multicentre double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J. Clin. Psychiatry 53 (1992, Suppl.) 57-60
40. Dunner, D. L., G. C. Dunbar: Optimal dose for regimen for paroxetine. J. Clin. Psychiatry 53 (1992, Suppl.) 21 -26
41. Eaton, W. W., R. C. Kessler, H. U. Wichen, W. J. Magee: Panic and panic disorder in the United States. Am. J. Psychiatry 151 (1994) 413-420
42. Eriksson, E., M. D. Hedberg, B. Andersch, C. Sundblad: The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 12 (1995) 167-176
43. Fawcett, J.: Targeting treatment in patients with mixed symptoms of anxiety and depression. J. Clin. Psychiatry 51 (1990, Suppl. 11) 40-43
44. Feighner, J. P., J. B. Cohn, L. F. Fabre, R. R. Fieve, J. Mendels, R. K. Shrivastava, G. C. Dunbar: A study comparing paroxetine placebo an imipramine in depressed patients. J. Affect. Disord. 28 (1993) 71-79
45. Fickinger, M. P., M. Philipp, O. Benkert, H. Schwarze, J. Angersbach: Paroxetine in depression: need for dose escalation. Neuropsychopharmacology 10 (1994) 47
46. Foster, C. A., J. Bafaloukos: Paroxetine in the treatment of chronic daily headache. Headache 34 (1994) 587-589
47. Frank, F., D. J. Kupfer, J. M. Perel, C. Cornes, D. B. Jarrett, A. G. Mollinger, M. E. Thase, A. B. McEachran, V. J. Grochocinski: Three-year outcomes for maintenance therapies in recurrent depression. Arch. Gen. Psychiatry 47 (1990) 1093-1099
48. Gagiano, C. A., P. G. M. Meller, J. Fourie, J. F. Le Roux: The therapeutic efficacy of paroxetine: (a) an open study in patients with major depression not responding to antidepressants (b) a double-blind comparison with amitriptyline in depressed outpatients. Acta Psychiatr. Scand. 80 (1989, Suppl. 350) 130-131
49. Gagiano, C. A.: A double-blind comparison of paroxetine and fluoxetine in patients with major depression. Br. J. Clin. Res. 4 (1993)145-152
50. Geretsegger, C., F. Bohmer, M. Ludwig: Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int. Clin. Psychopharmacol. 9 (1994) 25-29
51. Geretsegger, C., G. F. Hebenstreit, H. Hinterhuber, P. Konig, H. Schubert, T. Platz, A. Marneros: A multicentre, double-blind, randomized dose titration study comparing the efficacy and tolerability of oral paroxetine and amitriptyline in adult patients with major depression. Presented at the 5th World Congress of Biological Psychiatry, Florence, 1991
52. Gram, L. F., M. G. J. Hansen, S. H. Sindrup, K. Brosen, J. H. Poulsen, T. Aaes-Jorgensen, K. F. Overo: Citalopram: interaction studies with levopromazine, imipramine, and lithium. Therap. Drug Monit. 15 (1993) 18-24
53. Greenberg, P. E., L. E. Stiglin, S. N. Finkelstein, E. S. Berndt: Depression: a neglected major illness. J. Clin. Psychiatry 54 (1993a) 419-424
54. Guillibert, E., Y. Pelicier, J. C. Archambault, J. P. Chabammes, G. Clerc, M. Desvilles, M. Guibert, R. Pagot, J. L. Poissat, Y. Thobie: A double-blind, multicenter study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr. Scand. 80 (1989, Suppl. 350) 132-134
55. Haddad, P.: Newer antidepressants and the discontinuation syndrome. J. Clin. Psychiatry 58 (1997) 17-21
56. Hamilton, M.: Distinguishing between anxiety disorders. In: Last, C. A., M. Hersen (eds.): Handbook of anxiety disorders. Pergamon Press, New York (1988) pp. 143-145
57. Hamilton, T. C., J. Norton, R. H. Poyser, D. Thormählen: Comparison of some effects of paroxetine with amitriptyline on the cardiovascular system in animals. Arzneimittel Forschung 36 (1986) 460-463
58. Herman, J. B., A. W. Brotman, M. H. Pollack, W. E. Falk, J. Biederman, J. F. Rosenbaum: Fluoxetine-induced sexual dysfunction. J. Clin. Psychiatry 51 (1990) 25-27
59. Hirschfeld, R. M., A. F. Schatzberg: Long-term management of depression. Am. J. Med. 97 (1994) 33 S-38 S
60. Holliday, S. M., G. L. Plosker: Paroxetine: a review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. Drugs and Ageing 33 (1993) 278-299
61. Hunter, B., R. Judge: A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Presented at the International Academy for Biomedical and Drug Research Meeting, Bruges, 1996
62. Hunter, B.; A double-blind, multicentre study in primary care comparing paroxetine and clomipramine in patients with depression with associated anxiety. Eur. Neuropsychopharmacol. 5 (1995) 309, Abstract P2-101
63. Hutchinson, D. R., S. Tong, C. A. L. Moon, M. Vince, A. Clarke: A double-blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in depressed elderly patients. Br. J. Clin. Res. 2 (1991) 43-57
64. Jenner, P. N.: Paroxetine: an overview of dosage, tolerability and safety. Int. Clin. Psychopharmacol. 6 (1992, Suppl. 4) 69-80
65. Johnson, A. M.: The comparative pharmacological properties of selective serotonin reuptake inhibitors in animals In: Feighner, J. P., Boyer, W. F. (eds.): Perspectives in Psychiatry Vol 1. Wiley, Chichester (1991) pp. 37-70
66. Judge, R., G. C. Dunbar: Paroxetine, clomipramine and placebo in the treatment of panic disorder. Eur. Neuropsychopharmacol. 5 (1995) 361, Abstract P5-25
67. Judge, R., B. Hunter: Paroxetine in the treatment of depression associated with rheumatoid arthritis. Presented at the International Academy for Biomedical and Drug Research Meeting, Bruges, 1996
68. Judge, R., M. Steiner: The long-term efficacy and safety of paroxetine in panic disorder. Submitted to the 20th CINP Congress, Melbourne, 1996
69. Kanowski, S.: Age-dependent epidemiology of depression. Gerontology 40 (1994, suppl. 1) 1-4
70. Katon, W., M. D. Sullivan: Depression and chronic medical illness. J. Clin. Psychiatry 51 (1990, suppl 6) 3-11
71. Kiev, A.: A double-blind, placebo-controlled study of paroxetine in depressed outpatients. J. Clin. Psychiatry 53 (1992, Suppl. 2) 27-29
72. Kuhs, H., G. A. E. Rudolf: A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta Psychiatr. Scand. 80 (1989, Suppl. 350) 145-146
73. Kupfer, D. J., E. Frank, J. M. Perel, C. Cornes, A. G. Mallinger, M. E. Those, A. B. McEachrun, T. J. Grochodnski: Five-year outcome for maintenance therapies in recurrent depression. Arch. Gen. Psychiatry 49 (1992) 769-773
74. Lane, R. M.: A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J. Psychopharmacology 11 (1997) 72-82
75. Laruelle, M., C. Reynaert, A. Collin, S. Goffinet, A. Seghers, L. Cassiers: A multicentre double blind comparative study of paroxetine and maprotiline in major depression. Eur. Neuropsychopharmacol. 1 (1991) 439, P-63
76. Laursen, A. L., P. L. Mikkelsen, S. Rasmussen, P. le Fevre Honore: Paroxetine in the treatment of depression - a randomized comparison with amitriptyline. Acta Psychiatr. Scand. 71 (1985) 249-255
77. Lecrubier, Y.: Long-term treatment of depression. Eur. Psychiatry 8 (1993, Suppl. 1) 13-16
78. Lejoyeux, M., J. Ades: Antidepressant discontinuation: a review of the literature. J. Clin. Psychiatry 58 (1997) 11-15
79. Link, C., G. C. Dunbar: An overview of studies comparing the efficacy, safety and tolerability of paroxetine and clomipramine. Nord. J. Psychiatry 27 (1992, Suppl.) 17-22
80. MacDonald, T. M., A. D. McMahon, I. C. Reid, G. W. Fenton, D. G. McDevitt: Antidepressive therapy: prescription for success? Presented at the 8th Congress of the European College of Neuropsychopharmacology, Venice, 1995
81. Mancini, C. L., M. A. van Amerigen, C. Wilson: An open trial of paroxetine in social phobia. Presented at the 148th APA, Miami, 1995
82. Mann, J. J., A. Arango, P. M. Marzuk, S. Theccanat. D.J. Reis: Evidence for the 5 HT hypothesis of suicide: a review of post-mortem studies. Br. J. Psychiatry 155 (1989) 7-14
83. McClelland, C. R., P. Raptopoulos: Cardiovascular effects of paroxetine and amitriptyline after repeated administration to normal volunteers. Br. J. Clin. Pharmacol. 19 (1985) 282 P
84. McCombs, J. S., M. B. Nichol, G. L. Stimmel, D. A. Sclar, C. M. Beasley, L. S. Gross: The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J. Clin. Psychiatry 51 (1990, Suppl. 6) 60-71
85. McGilp, R.: Case report. Paroxetine and delayed ejaculation - a treatable effect. J. Drug Development 5 (1993) 265-266
86. Montgomery, S. A., G. Dunbar: Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. J. Clin. Psychopharmacol. 8 (1993) 189-195
87. Montgomery, S. A., D. L. Dunner, G. C. Dunbar: Reduction in suicidal thoughts with paroxetine in comparison with reference anti-depressants and placebo. Eur. Neuropsychopharmacol. 5 (1995) 5-13
88. Montgomery, S. A., J. Henry, G. McDonald, T. Dinan, M. Lader, I. Hindmarch, A. Clare, D. Nutt: Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int. Clin. Psychopharmacol. 9 (1994) 47-53
89. Montgomery, S. A., D. B. Montgomery: Prophylactic treatment in recurrent unipolar depression. In: Montgomery, S. A., F. Rouillon (eds.): Long-term treatment of depression. John Wiley, Chichester (1992)
90. Montgomery, S. A.: The advantages of paroxetine in different subgroups of depression. Int. Clin. Psychopharmacol. 6 (1992, Suppl. 4) 91-100
91. Montgomery, S. A.: Severe depression: TCAs or SSRIs? Int. Clin. Psychopharmacol. 1996
92. National Institute of Mental Health Consensus Development Conference Statement: Mood disorders: pharmacologic prevention of recurrences. Am. J. Psychiatry 142 (1985) 469-476
93. Nemeroff, C. B.: Evolutionary trends in the pharmacotherapeutic management of depression. J. Clin. Psychiatry 55 (1994, Suppl.) 3-15
94. Nemeroff, C. B., C. L. De Vane, B. G. Pollock: Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry 153 (1996) 311-320
95. Norden, M. J.: Buspirone treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Depression 2 (1994) 109-111
96. Oehrberg, P. E., P. E. Christiansen, K. Behnke, A. L Borup, B. Severin, J. Soegaard, H. Calberg, R. Judge, J. K. Ohrstrom, P. M. Manniche: Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. Br. J. Psychiatry 167 (1995) 374-379
97. Ontiveros, A., C. Garcia-Barriga: A double-blind study with paroxetine and fluoxetine in depressive patients. Biol. Psychiatry 35 (1994) 677
98. Ormel, J., M. von Korff, T. B. Ustun, S. Pini, A. Korten, T. Oldehinkel: Common medical disorders and disability across cultures. JAMA 272 (1994) 1741-1748
99. Overo, K. F.: Preliminary studies of the kinetics of citalopram in man. Eur. J. Pharmacol. 14 (1978) 69-73
100. Pitts, C. D., M. L. Young, R. Oakes, I. Gergel: Comparative safety of paroxetine versus imipramine in the treatment of bipolar depression. Psychopharmacology Bulletin 33 (1997) 568
101. Reimherr, F. W., G. Chouinard, C. K. Cohn, J. O. Cole, T. M. Itil, Y. D. Lapierre, M. D. Masco, J. Mendels: Antidepressant efficacy of sertraline: a double-blind, placebo-and -amitriptyline-controlled multicenter comparison in outpatients with major depression. J. Clin. Psychiatry 51 (1990, Suppl. B) 18-27
102. Rickets, K., J. Amsterdam, C. Clary, I. Fox I, E. Schweizer, C. Weise: The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. J. Clin. Psychiatry 53 (1992, Suppl. 2) 31-32
103. Rickels, K., E. Schweizer: The treatment of generalized anxiety disorder in patients with depressive symptomatology. J. Clin. Psychiatry 54 (1993, Suppl. 1) 20-23
104. Rodríguez-Ramos, P., J. L. de Dios Vega, J. S. S. Cabases, L. S. Sordo, M. J. M. Sanz: Paroxetine for treating depression in adolescents. Eur. J. Clin. Res. 8 (1996) 49-61
105. Roose, S., B. Pollock, J. Kennedy, J. Nelson, I. Gergel, J. McCafferty, W. Bushnell, R. Kumar: Paroxetine in the treatment of depressed patients with ischaemic heart disease. Presented at the World Congress of Biological Psychiatry, June 1997
106. Rouillon, F.: A double-blind, multicentre study comparing increasing doses of paroxetine (20-50mg) and clomipramine (50-150mg) in elderly patients with major depression. Presented at a the 5th World Congress of Biological Psychiatry, Florence, 1991
107. Roy-Byrne, P. P., A. J. Elliott, K. Uldall, Russo, K. Claypoole, K. Bergam: A placebo-controlled trial of paroxetine vs imipramine in depressed HIV+ outpatients. Submitted for publication
108. Samueliun, J. C.: A dose titration study comparing the efficacy and tolerability of paroxetine and clomipramine in elderly out-patients with moderate depression. Presented at a the 5th World Congress of Biological Psychiatry, Florence, 1991
109. Schatzberg, A. F.: Dosing strategies for antidepressant agents. J. Clin. Psychiatry 52 (1991, Suppl.) 14-20
110. Schmider, J., D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, R. I. Shader: N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP 3A) isoforms and effect of metabolic inhibitors. J. Pharmacol. Exp. Ther. 275 (1995) 592-597
111. Schöne, H. M., M. Ludwig: A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J. Clin. Psychopharmacol. 13 (1993, Suppl.) 34-39
112. Sedgwick, E. M., J. Cilasun, J. G. Edwards: Paroxetine and the electroencephalogram. J. Psychopharmacol. 1 (1987) 31-34
113. Segraves, R. T.: Treatment of drug-induced anorgasmia. Brit. J. Psychiatry 165 (1994) 554
114. Sheehan, D., G. C. Dunbar, D. L. Fuell: The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacol. Bull. 28 (1992) 139-143
115. Sheehan, D. V., B. A. Raj, R. R. Trehan, E. L. Knapp: Serotonin in panic disorder and social phobia. Int. J. Clin. Psychopharmacol. 8 (1993, Suppl. 2) 63-77
116. th CINP Congress, Kyoto 1990
117. Shrivastava, R. K.: Efficacy trial: paroxetine and fluoxetine in depression. Presented at the Annual Meeting of the American Psychiatric Association, 1993
118. Smith, W. T., V. Glaudin: A placebo-controlled trial of paroxetine in the treatment of major depression. J. Clin. Psychiatry 53 (1992, Suppl. 2) 36-39
119. Stanley, M., J. Virgilio, S. Gershon: Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science 216 (1982) 1337-1339
120. rd Annual Meeting of the American College of Neuropsychopharmacology, Puerto Rico, 1994
121. Steiner, M.; Long-term treatment and prevention of relapse in OCD with paroxetine. Presented at the Annual Meeting of the American Psychiatric Association, Miami, 1995
122. Stott, P. C., M. D. Blagden, C. A. Aitken: Depression and associated anxiety in primary care: A double-blind comparison of paroxetine and amitriptyline. European Neuropsychopharmacology 3 (1993) 324-325
123. Thase, M. E.: Long-term treatment of recurrent depressive disorders. J. Clin. Psychiatry 53 (1992, Suppl.) 32-34
124. Thase, M. E., M. Fava, U. Halbreich, J. H. Kocsis, L. Koran, J. Davidson, J. Rosenbaum, W. Harrison: A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch. Gen. Psychiatry 53 (1996) 777-784
125. Tignol, J.: A double-blind, randomized, fluoxetine-controlled, multicentre study of paroxetine in the treatment of depression. J. Clin. Psychopharmacol. 13 (1993a) 18 S-22 S
126. Tignol J.: Treatment of severe depression with paroxetine. Eur. Psychiatry 8 (1993b, Suppl. 1) 21-23
127. Tyrer, P., C. A. Marsden, P. Casey, N. Seivewright: Clinical efficacy of paroxetine in resistant depression. J. Psychopharmacol. 4 (1987) 251-257
128. Viale, G. L., S. Calvert, B. K. Uyeda: Economic analysis of physician prescribing habits of SSRIs in a naturalistic setting. Presented at the annual seminar of the California Society of Hospital Pharmacists, October 1994
129. Warrington, S. J., J. Dana-Haeri, A. J. Sinclair: Cardiovascular and psychomotor effects of repeated doses of paroxetine: a comparison with amitriptyline and placebo in healthy men. Acta Psychiatr. Scand. 80 (1989, Suppl. 350) 42-44
130. Weissman, M. M., R. C. Bland, G. J. Canino, S. Greenwald, H.-G. Hwu, C. K. Lee, S. C. Newman, M. A. Oakley-Browne, M. Rubio-Stipec, P.J. Wickramaratne, H.-U. Wittchen, E.-K. Yeh: The cross national epidemiology of obsessive compulsive disorder. J. Clin. Psychiatry 55 (1994, Suppl. 3) 5-10
131. Wells, K. B., A. Stewart, R. D. Hays, A. Burnam, W. Rogers, M. Daniels, S. Berry, S. Greenfield, J. Ware: The functioning and well being of depressed patients. Results from the medical outcomes study. JAMA 262 (1989) 914-919
132. nd Annual Meeting of the American College of Neuropsychopharmacology, 1993
133. Yokota, S., Y. Ishikura, H. Ono: Cardiovascular effects of paroxetine, a newly developed antidepressant, in anaesthetized dogs in comparison with those of imipramine, amitriptyline, and clomipramine. Jap. J. Pharmacol. 45 (1987) 335-342
134. Yonkers, K. A., A. S. Williams, K. Novak, A. J. Rush: Paroxetine for the treatment of premenstrual dysphoric disorder. Neuropsychopharmacology 10 (1994) 99
135. Zohar, J., R. Judge: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br. J. Psychiatry (1996)
136. Zussman, B. D., C. C. Davie, S. E. Fowles, R. Kumar, U. Lang, M. Wargenau, H. Sourgens: Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br. J. Pharmacol. 39 (1995) 550-551 P